Recently, generation of cytotoxic T cells targeting PRAME antigens for the treatment of acute myeloid leukemia, chronic myeloid leukemia, and medulloblastoma has been reported (23, 24, 32). This evidence concerns the gene PRAME and chronic myelogenous leukemia, BCR-ABL1 positive.